Mp45-06 clinical significance of α2,3-sialylated prostate-specific antigen density and mri for high-grade prostate cancer in biopsy-naïve men with elevated psa level

You have accessJournal of UrologyCME1 May 2022MP45-06 CLINICAL SIGNIFICANCE OF α2,3-SIALYLATED PROSTATE-SPECIFIC ANTIGEN DENSITY AND MRI FOR HIGH-GRADE PROSTATE CANCER IN BIOPSY-NAÏVE MEN WITH ELEVATED PSA LEVEL Tohru Yoneyama, Shingo Hatakeyama, Mihoko Sutoh Yoneyama, Yuki Tobisawa, Takuma Narita, Hirotake Kodama, Masaki Momota, Hiroyuki Ito, Shintaro Narita, Fumiyasu Tsushima, Koji Mitsuzuka, Takahiro Yoneyama, Yasuhiro Hashimoto, Wilhelmina Duivenvoorden, Jehonathan H. Pinthus, Shingo Kakeda, Akihiro Ito, Norihiko Tsuchiya, Tomonori Habuchi, and Chikara Ohyama Tohru YoneyamaTohru Yoneyama More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Mihoko Sutoh YoneyamaMihoko Sutoh Yoneyama More articles by this author , Yuki TobisawaYuki Tobisawa More articles by this author , Takuma NaritaTakuma Narita More articles by this author , Hirotake KodamaHirotake Kodama More articles by this author , Masaki MomotaMasaki Momota More articles by this author , Hiroyuki ItoHiroyuki Ito More articles by this author , Shintaro NaritaShintaro Narita More articles by this author , Fumiyasu TsushimaFumiyasu Tsushima More articles by this author , Koji MitsuzukaKoji Mitsuzuka More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , Wilhelmina DuivenvoordenWilhelmina Duivenvoorden More articles by this author , Jehonathan H. PinthusJehonathan H. Pinthus More articles by this author , Shingo KakedaShingo Kakeda More articles by this author , Akihiro ItoAkihiro Ito More articles by this author , Norihiko TsuchiyaNorihiko Tsuchiya More articles by this author , Tomonori HabuchiTomonori Habuchi More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002611.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To reduce unnecessary biopsies, biomarker discriminating high-grade prostate cancer (HGPC) greater than grade group 2 are needed. The presence of α2,3-sialylated prostate-specific antigen (S2,3PSA) in sera with prostate cancer (PC) patients is a potential marker of their aggressiveness. The objective was to characterized the origin of S2,3PSA in prostate tissue, and studied the clinical performance of %S2,3PSA density (%S2,3PSAD) alone and in combination with MRI for the detection of high-grade PC (HGPC) in men with elevated PSA. METHODS: %S2,3PSA of benign and cancer tissue was measured in 71 radical prostatectomy specimens. The diagnostic performance of %S2,3PSA density (%S2,3PSAD) alone (primary outcome) and %S2,3PSAD combined with Prostate Imaging Reporting and Data System (PI-RADS) scores (secondary outcome) was evaluated by retrospective systematic biopsy cohort (n = 654) and prospective MRI-targeted biopsy cohort (n = 79) respectively, analyzed using ROC and DCA analysis. RESULTS: %S2,3PSA was significantly higher in Gleason pattern 4 and 5 tissues compared to benign prostate tissue. In the retrospective cohort, the AUC of %S2,3PSAD for detecting HGPC was superior to total PSA (tPSA) or PSA density (PSAD) (0.7704 vs. 0.5431 and 0.7140, all p <0.001). In the prospective cohort, %S2,3PSAD was superior to tPSA, PSAD, and PI-RADS (AUC: 0.8194 vs. 0.5058, 0.7177 and 0.7661, all p <0.05) and biopsy avoidance rate of %S2,3PSAD+PI-RADS+tPSA+digital rectal examination (DRE) was superior to PI-RADS+tPSA+DRE (24% vs. 13.9%) at 30% risk threshold. CONCLUSIONS: The diagnostic performance of %S2,3PSAD was superior to conventional strategies but comparable to MRI. Source of Funding: This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (grant nos. 15K15579 and 15H02563) and also supported by Sakurai Memorial Medical Research Foundation © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e764 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tohru Yoneyama More articles by this author Shingo Hatakeyama More articles by this author Mihoko Sutoh Yoneyama More articles by this author Yuki Tobisawa More articles by this author Takuma Narita More articles by this author Hirotake Kodama More articles by this author Masaki Momota More articles by this author Hiroyuki Ito More articles by this author Shintaro Narita More articles by this author Fumiyasu Tsushima More articles by this author Koji Mitsuzuka More articles by this author Takahiro Yoneyama More articles by this author Yasuhiro Hashimoto More articles by this author Wilhelmina Duivenvoorden More articles by this author Jehonathan H. Pinthus More articles by this author Shingo Kakeda More articles by this author Akihiro Ito More articles by this author Norihiko Tsuchiya More articles by this author Tomonori Habuchi More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement PDF DownloadLoading ...